Bulletin
Investor Alert

Topics

Canada

Video

Coronavirus Could Make It Harder to Stock Your Medicine Cabinet

  • Coronavirus Could Make It Harder to Stock Your Medicine Cabinet Coronavirus Could Make It Harder to Stock Your Medicine Cabinet 1:49
    Kodak's Decline Took Decades; Its Comeback Fell Through in a Flash Kodak's Decline Took Decades; Its Comeback Fell Through in a Flash 8:11
4:28 a.m. July 7, 2021 - By Tomi Kilgore
Tilray completes first harvest of medical cannabis for distribution at German pharmaciesTilray Inc. said its Germany-based subsidiary Aphria RX GmbH has completed the first successful harvest of medical cannabis, which was cultivated in Germany, for distribution to pharmacies. Tilray's stock rose 0.4% in premarket trading. The Canada-based cannabis company said the harvest if the first cultivated at its indoor growing facility in Neumunster, Germany. The distribution was carried about by a distributor on behalf of the German Cannabis Agency. "Our harvest in Germany represents an important milestone in granting access to high-quality and trustworthy medical cannabis to patients and healthcare professionals in Germany," said Tilray's Chief Strategy Officer Denise Faltischek. Shares of Tilray, which is the world's largest cannabis company by revenue following the recent completion of its merger with Aphria, have soared 102.4% year to date through Tuesday, while the Cannabis ETF has rallied 33.1% and the S&P 500 has gained 15.6%.
12:26 p.m. June 28, 2021 - By Catey Hill
What it’s really like to retire on a Caribbean island — on $3,000 a month This Virginia couple retired to the Caribbean island of Bequia and opened an art galleryThis Virginia couple retired to the Caribbean island of Bequia and opened an art gallery.
4:41 a.m. June 15, 2021 - By Jaimy Lee
Ocugen's stock is up 14% after announcing manufacturing partner for experimental COVID-19 shotShares of Ocugen Inc. gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still-investigational COVID-19 vaccine for the U.S. and Canada. The vaccine is not authorized or approved in either country at this time. Ocugen's stock is up 239.4% so far this year, while the broader S&P 500 has gained 13.3%.
3:51 a.m. June 7, 2021 - By Tomi Kilgore
Moderna submits for marketing approval of COVID-19 vaccine in adolescents in EuropeShares of Moderna Inc. rose 0.5% in premarket trading Monday, after the biotechnology company said it had submitted for conditional market approval (CMA) with the European Medicines Agency (EMA) for its COVID-19 vaccine in adolescents, ages 12 to less than 18. In May, the company said the Phase 2/3 study of its vaccine in adolescents met its primary immunogenicity endpoint. "We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents," said Chief Executive Stéphane Bancel. "We have filed for authorization with Health Canada and we will file for an Emergency Use Authorization with the U.S. FDA and regulatory agencies around the world for this important younger age population." Moderna's stock has soared 97.3% year to date through Friday, while the S&P 500 has gained 12.6%.
3:29 a.m. June 2, 2021 - By Jaimy Lee
Moderna signs deal to provide up to 466 million doses of its COVID-19 shot to UnicefShares of Moderna Inc. were down 0.2% in premarket trading on Wednesday after it announced a deal with Unicef to supply 34 million doses of its COVID-19 vaccine in the fourth quarter of 2021 and up to 466 million doses of its mRNA shot in 2022. Moderna's stock is up 76.7% for the year, while the broader S&P 500 has gained 11.8%. Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On November 30, 2020, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. On November 30, 2020, the Company also announced that it filed for Emergency Use Authorization with the U.S.FDA and a Conditional Marketing Authorization (CMA) application with the European Medicines Agency. On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has also received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, the Philippines, Thailand, Brunei, Paraguay, Japan, South Korea and an Emergency Use Listing (EUL) from the World Health Organization (WHO). Initial data from Moderna's Phase 2 study in the U.S. showed that a single 50 µg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351 (first identified in South Africa) and P.1 (first identified in Brazil). A booster dose of mRNA-1273.351, the Company's strain-matched booster, achieved higher neutralizing antibody titers against the B.1.351 variant of concern than a booster dose of mRNA-1273. Safety and tolerability profiles following third dose booster injections of 50 µg of mRNA-1273 or mRNA-1273.351 were generally comparable to those observed after the second dose of mRNA-1273 in the previously reported Phase 2 and Phase 3 studies. A manuscript describing these preliminary results was submitted as a preprint to medRxiv and will be submitted for peer-reviewed publication upon completion of the multivalent mRNA-1273.211 booster arm. About Moderna
1:26 p.m. May 14, 2021 - By Claudia Assis
Medical-device maker Femasys files for IPOMedical-device maker Femasys Inc. has filed for an initial public offering. The Georgia-based company, which focuses on women's health care, filed to sell $40.25 million worth of shares. The company plans to list its shares on the Nasdaq under the symbol FEMY, according to a filing with U.S. securities regulators on Friday. Femasys said its sales rose 12% to $1.04 million in 2020, and its net loss narrowed to $6.9 million in 2020 from an $11.3 million net loss in 2019. One of its devices, FemVue, used in artificial inseminations, has marketing clearances or authorization in the U.S., Europe, Canada, and Japan, but currently its sale is "a very limited direct effort," the company said.
6:42 a.m. May 5, 2021 - By Jaimy Lee
Canada authorizes Pfizer's COVID-19 vaccine for kids between the ages of 12 and 15 years oldShares of Pfizer Inc. gained 2.5% in trading on Wednesday after Canadian regulators said they authorized using the company's COVID-19 vaccine for children between the ages of 12 and 15 years old. Pfizer developed the vaccine in partnership with BioNTech SE . Health Canada said in a news release that this is the first coronavirus vaccine that has been authorized for this age group. The vaccine is also expected to receive emergency-use authorization for the same age group in the U.S. sometime in the next week. Pfizer's stock has gained 8.3% since these start of the year, while the S&P 500 is up 11.6%. Health Canada received an application to expand the indication of Pfizer-BioNTech's COVID-19 vaccine on April 16, 2021. The vaccine was initially authorized for use in people 16 years of age and older on December 9, 2020.
3:35 a.m. April 7, 2021 - By Ciara Linnane
Bausch Health to reduce debt by $100 million using cash from operationsBausch Health Companies Inc. said Wednesday it will reduce debt by another $100 million using cash from operations to redeem its outstanding 7.00% senior secured notes due in 2024. The company, the former Valeant, already redeemed $200 million aggregate principal amount of the bonds in March. Bausch has been working for years to reduce a high debt load that was taken on by the former Valeant during a yearslong acquisition spree. The company had $23.9 billion in long-term debt at end-December, according to FactSet data. Shares were not yet active premarket, but have gained 50% in the year to date, while the S&P 500 has gained 8.3%.
3:51 a.m. March 30, 2021 - By Steve Goldstein
German regulator reportedly says nine have died from blood clots after taking AstraZeneca vaccineGermany's vaccine regulator said nine people have died from a rare blood clot in the brain after taking the AstraZeneca coronavirus vaccine, , citing a statement from the Paul Ehrlich Institute. Seven of the deaths were in women between 20 and 63 years old. Canada on Monday suspended the use of the Oxford-AstraZeneca coronavirus vaccine for people under age 55 on blood clot concerns.
9:11 a.m. March 18, 2021 - By Robert Schroeder
U.S. plans to send AstraZeneca vaccine doses to Canada, Mexico: White HouseThe U.S. is planning to send 4 million doses of the AstraZeneca COVID-19 vaccine to Mexico and Canada, the White House said Thursday. White House press secretary Jen Psaki described the arrangements as loans, with 2.5 million doses going to Mexico and 1.5 million doses for Canada. She said the Biden administration's priority remains vaccinating Americans first, but "the pandemic knows no borders." The AstraZeneca vaccine is not yet authorized for use in the U.S. Earlier Thursday, Europe's drug regulator that the AstraZeneca vaccine is "safe and effective," following its investigation into reports of blood clots in people that had received the shot.
7:33 a.m. March 5, 2021 - By Jaimy Lee
Canada authorizes J&J's COVID-19 vaccineShares of Johnson & Johnson gained 1.4% in trading on Friday after Canada's health regulatory body said it authorized the company's COVID-19 vaccine. The single-dose vaccine in the U.S. on Saturday. J&J's stock has gained 8.7% over the past year, while the broader S&P 500 is up 20.4%.
9:45 a.m. Feb. 18, 2021 - By Tomi Kilgore
Pfizer, BioNTech have started trial to evaluate their COVID-19 vaccine in pregnant womenPfizer Inc. and partner BioNTech SE said Thursday that they have commenced a clinical trial to evaluate their COVID-19 vaccine in pregnant women. The companies said the Phase 2/3 trial will enroll 4,000 health pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, the United Kindom and Spain, with the first participants dosed in the U.S. "We are proud to start this study in pregnant women and continue to gather the evidence on safety and efficacy to potentially support the use of the vaccine by important subpopulations," said William Gruber, senior vice president of vaccine clinical research and development at Pfizer. "Pregnant women have an increased risk of complications and developing severe COVID-19, which is why it is critical that we develop a vaccine that is safe and effective for this population." Pfizer and BioNTech said they expect to start studies in children between the ages of 5 and 11 years over the next couple months, and in children younger than 5 later this year. Pfizer's stock fell 0.8% in afternoon trading and BioNTech shares lost 1.4%, while the S&P 500 declined 0.6%.
6:59 a.m. Feb. 10, 2021 - By Jaimy Lee
Moderna to supply 10 million doses to Colombia, 5 million doses to TaiwanShares of Moderna Inc. were up 0.1% in trading on Wednesday, the day after the company said it plans to supply 5 million doses of its COVID-19 vaccine to Taiwan and another 10 million doses to Colombia, starting in mid-2021. Neither country has authorized the vaccine. Moderna's vaccine, an mRNA-based two-dose shot, so far has been authorized in Canada, the European Union, and the U.S., among other nations. Its stock has soared 660.9% over the past 12 months, while the broader S&P 500 is up 17.5%.
10:13 a.m. Feb. 3, 2021 - By Victor Reklaitis
White House says review underway after Canada designates Proud Boys as terrorist groupWhite House press secretary Jen Psaki on Wednesday said the Biden administration's national security team is taking "a look at violence and this type of concerning group activity across the country," when she was asked about the Proud Boys as a terrorist entity. "I expect we will wait for that review to conclude before we make any determinations," Psaki told reporters.
12:31 p.m. Jan. 12, 2021 - By Jeremy C. Owens
Bausch Health says annual revenue will exceed guidance, stock gains Bausch Health Corp. shares gained more than 5% in after-hours trading Tuesday after the company announced that its annual revenue will come in higher than its guidance. Bausch Health, formerly known as Valeant Pharmaceuticals before a scandal that led to large-scale changes at the company, said that fourth-quarter revenue would top $2.2 billion and lead annual sales to come in higher than the top end of its guidance range, $8 billion. "We also expect a strong finish to the year with regard to Adjusted Ebitda,' Chief Executive Joseph Papa said in a statement, without providing any figures on profit. The disclosure arrived before Bausch executives speak Wednesday morning at the JP Morgan Healthcare Conference on recent accomplishments; full results are expected to be released next month. Bausch stock closed with a 0.1% decline at $23.47, and topped $25 in after-hours trades following the release of the information.
4:21 a.m. Jan. 2, 2021 - By Philip van Doorn
15 stock-market winners that index-fund investors missed out on in 2020 These stocks aren’t in the S&P 500 or the Nasdaq-100These stocks aren’t in the S&P 500 or the Nasdaq-100.
4:17 a.m. Jan. 2, 2021 - By Philip van Doorn
These are the best performing Nasdaq and S&P 500 stocks of 2020 COVID-19 rewarded companies at the cutting edge of mobility and remote workingCOVID-19 rewarded companies at the cutting edge of mobility and remote working.
2:05 a.m. Dec. 29, 2020 - By Ciara Linnane
Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion Companies are also seeking approval for drug as treatment for unmet women’s health needsShares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health in a deal worth up to $4.2 billion in upfront and potential milestone payments.
4:33 a.m. Dec. 28, 2020 - By Ciara Linnane
UPDATE: Myovant shares soar 20% premarket on news of Pfizer cancer drug deal worth up to $4.2 billionShares of Myovant Sciences soared 20% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a deal worth up to $4.2 billion in upfront and potential milestone payments. Myovant will receive an upfront payment of $650 million to develop relugolix, a once-daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women's health in the U.S. and Canada. Pfizer will have the exclusive right to commercialize relugolix in oncology outside the U.S. and Canada, excluding some Asian countries. Myovant is one of five companies under the Sumitovant umbrella. "Myovant and Pfizer will jointly develop and commercialize ORGOVYX(TM) (relugolix) in advanced prostate cancer and, if approved, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women's health in the U.S. and Canada," the companies said in a joint statement. The U.S. Food and Drug Administration approved Orgovyx on Dec. 18 as a treatment for advanced prostate cancer. Pfizer shares were slightly higher premarket and have gained 0.4% in the year to date, while the S&P 500 has gained 15%.
7:42 a.m. Dec. 23, 2020 - By Jaimy Lee
Canada authorizes Moderna's COVID-19 vaccineShares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. The government there has committed to buying 40 million doses of the vaccine, which requires two doses for each person. The company's vaccine in the U.S. last week. Moderna's stock has soared 542.3% this year, while the S&P 500 is up 14.1%.
8:57 a.m. Dec. 14, 2020 - By Nicole Lyn Pesce
WATCH: Relieved Americans applaud as the Pfizer-BioNTech COVID-19 vaccine rolls out across the country Queens, N.Y., nurse Sandra Lindsay received the first COVID-19 vaccine in the U.S. on Monday morning Queens, N.Y., nurse Sandra Lindsay received the first COVID-19 vaccine in the U.S. on Monday morning
10:55 a.m. Dec. 11, 2020 - By Ciara Linnane
U.S. suffers its worst week of cases, deaths and hospitalizations since the start of the pandemic CDC head warns U.S. will see more deaths every day for next few months than died on Sept. 11, 2001, or in the attack on Pearl HarborThe U.S. suffered its worst week for cases, deaths and hospitalizations with the coronavirus illness COVID-19, as the Food and Drug Administration said it would grant emergency use authorization to the vaccine developed by Pfizer Inc. and its Germany partner BioNTech SE.
10:22 a.m. Dec. 10, 2020 - By Ciara Linnane
U.S. sets record one-day death toll from coronavirus as FDA committee meets to review Pfizer–BioNTech vaccine FDA head says initial assessment is ‘this is a vaccine that does meet our criteria. ... But we do want to hear from the vaccine advisory committee.’The U.S. set fresh records for single-day fatalities from the coronavirus illness COVID-19 and hospitalizations, as a U.S. regulatory advisory committee gathered to offer its verdict on the vaccine developed by Pfizer Inc. and its German partner BioNTech SE.
10:26 a.m. Dec. 9, 2020 - By Ciara Linnane
U.S. coronavirus case tally climbs to 15 million from 14 million in just five days U.S. sets fresh record for COVID-19 hospitalizations; Angela Merkel pleads with Germans to limit gatherings during holidaysThe global case tally for the coronavirus illness COVID-19 climbed above 68 million on Wednesday and the U.S. tally rose above 15 million as the virus continued to race across the nation, filling hospitals with record numbers of patients
8:37 a.m. Dec. 9, 2020 - By Jaimy Lee
Canada authorizes BioNTech/Pfizer COVID-19 vaccineShares of BioNTech were down 0.6% and Pfizer Inc.'s stock fell 1.1% in trading on Wednesday after the companies announced that their COVID-19 vaccine candidate had received emergency authorization in Canada. This is the third country, after Bahrain and the United Kingdom, to authorize their coronavirus vaccine. The regulatory approval in Canada was granted to BioNTech; Pfizer has commercialization rights. The Canadian government previously signed a deal for 20 million doses of the two-dose vaccine, with an option to acquire up to 76 million doses, through 2021. The Food and Drug Administration this week is expected to grant authorization to the vaccine as soon as Thursday, according to New York Gov. Andrew Cuomo's Wednesday morning . This would make the BioNTech/Pfizer vaccine the first vaccine to receive authorization in the U.S. So far this year, shares of BioNTech are up 276.1%, Pfizer's stock has gained 13.6%, and the S&P 500 is up 14.6%.
7:40 a.m. Dec. 7, 2020 - By Ciara Linnane
New dynamic COVID-19 tracking system aims to help localities predict where virus is headed — and whether it’s accelerating ‘We can inform leaders where the outbreak is occurring before it shows up in overcrowded hospitals and morgues,’ says lead co-authorA group of academics and health experts are launching a dynamic COVID-19 tracking system that will help counties, states and metropolitan areas predict where the virus is headed, when it will arrive and whether spread is accelerating.
5:41 a.m. Dec. 7, 2020 - By Tomi Kilgore
Moderna's stock rallies after Canada doubles order for COVID-19 vaccine candidateShares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for . Canada has exercised its option to order an additional 20 million doses of the vaccine candidate, bringing the confirmed order commitment to 40 million doses. Moderna said it remains on track to begin shipping its vaccine candidate, mRNA-1273, this month if regulatory approval to do so is granted. The vaccine supply for Canada will be sourced from Moderna's production capacity in Europe. Moderna has initiated the review process with Health Canada and plans to seek Prequalification and/or Emergency Use Listing (EUL) with the World Health Organization. The stock has more than doubled over the past three months (up 146.8%), while the S&P 500 has gained 7.8%.
4:38 a.m. Dec. 7, 2020 - By Tomi Kilgore
AbCellera Biologics sets terms of IPO, which could value the company at up to $4.5 billionAbCellera Biologics Inc. said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion. The Vancouver-based company, which is . on a COVID-19 therapy, said it is offering 23 million shares in the IPO, which is expected to price between $14 and $17 a share, which means the company could raise as much as $391 million. The company expects to have 265.95 million shares outstanding after the IPO. The shares are expected to list on the Nasdaq under the ticker symbol "ABCL." Credit Suisse, Stifel, Berenberg, SVG Leerink and BMO Capital Markets are the underwriters. For the nine months ended Sept. 30, the company reported net income of $1.9 million on revenue of $25.2 million, after a loss of about $570,000 on revenue of $8.4 million in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has hiked up 38.0% over the past three months while the S&P 500 has gained 7.9%.
4:31 a.m. Dec. 5, 2020 - By Ciara Linnane
Aurora leads cannabis sector rally fueled by hopes for reform under President-elect Joe Biden News that Mexico’s senate has approved a cannabis legalization bill offers further boost to battered sectorAurora Cannabis Inc. led a rally in the weed sector Tuesday that was fueled by hopes President-elect Joe Biden, finally cleared to move ahead with his administration’s transition, will push for reforms that will let companies access banks and capital markets.
10:50 a.m. Dec. 1, 2020 - By Ciara Linnane
U.S. is heading for 100,000 COVID-19 patients in hospitals as experts worry about a coming Thanksgiving travel spike ‘What happened during Thanksgiving is a lot like a 100-mile-an-hour wind going into a forest fire,’ says epidemiologist Michael OsterholmThe U.S. set a record for hospitalizations with the coronavirus illness COVID-19 on Tuesday at almost 100,000 patients and health experts worried that the situation will worsen in the coming weeks after millions traveled across the country for the Thanksgiving holiday.
3:01 a.m. Nov. 29, 2020 - By Andrew Keshner
Americans pay more for prescription drugs than anyone else. Can Amazon Pharmacy change that? What the e-commerce behemoth’s entry into the pharmacy business could mean for consumers’ health and wealthWhat the e-commerce behemoth’s entry into the pharmacy business could mean for consumers’ health and wealth
11:03 a.m. Nov. 27, 2020 - By Ciara Linnane
U.S. sets record of more than 90,000 COVID-19 patients in hospitals and health-care workers warn situation is dire CDC model estimates that true U.S. case tally was close to 58 million through September and is closer to 100 million now The U.S. set a fresh record for hospitalizations with the coronavirus illness COVID-19 on Thanksgiving Day, with more than 90,000 Americans in U.S. hospitals, the most since the start of the pandemic.
10:55 a.m. Nov. 25, 2020 - By Ciara Linnane
Hospital workers called exhausted as U.S. records highest number of COVID deaths since May Parts of Europe are reporting declining cases and Sicily has asked Cuba to send doctors and nursesThe U.S. recorded the highest number of deaths from the coronavirus illness COVID-19 since May on Tuesday, and continues to average close to 200,000 new cases a day, with hospitals across the nation reporting exhausted health care workers and steadily filling intensive care units.
10:23 a.m. Nov. 10, 2020 - By Ciara Linnane
Cannabis rally takes a pause as lackluster earnings make gains look overdone Aurora’s numbers ‘are not really standing out as anything special or overly encouraging,’ says analystThe strong rally that has propelled cannabis stocks higher since Democrat Joe Biden won the 2020 presidential election took a pause on Tuesday, as analysts weighed in on earnings from three industry heavyweights and found little to justify some of the explosive gains.
3:56 a.m. Nov. 10, 2020 - By Ciara Linnane
As pot stocks boom on hopes for U.S. legalization, Canadian cannabis companies struggle for growth Cannabis Watch: Canopy revenue grows, but Tilray’s sales are stagnant and Aurora sales decline while a prominent partnership costs $40 million to endAfter huge stock gains on the hopes of a larger market for legal pot in the U.S., Canadian cannabis companies didn’t offer much to justify the exuberance Monday.
10:00 a.m. Nov. 6, 2020 - By Alessandra Malito
News and analysis for those planning for or living in retirement Retirement news and analysisRetirement news and analysis
1:18 p.m. Nov. 4, 2020 - By Philip van Doorn
These stocks rose the most Wednesday as investors cheered a divided government following the elections The Nasdaq Composite Index jumped 3.9%, led by tech and health-care stocksThe Nasdaq Composite Index jumped 3.9%, led by tech and health-care stocks.
12:17 p.m. Nov. 3, 2020 - By Alessandra Malito
Even with a toddler, this couple’s cost of living is less than $25,000 a year — this is how they do it They tackled student loans, paid down a mortgage and reached financial independence in their 30sThey tackled student loans, paid down a mortgage, and reached financial independence in their 30s
3:16 a.m. Nov. 3, 2020 - By Ciara Linnane
Bausch Health tops revenue estimates and reiterates guidanceBausch Health Cos. Inc. shares rose 5% in premarket trade Tuesday, after the drug company's better-than-expected revenue offset weaker-than-expected profit. Bausch, the former Valeant, posted net income of $71 million, or 20 cents a share, for the quarter, after a loss of $49 million, or 14 cents a share, in the year-earlier period. Revenue fell to $2.138 billion from $2.209 billion. The FactSet consensus was for EPS of $1.02 and revenue of $2.032 billion. The numbers, "clearly demonstrate our recovery from the COVID-19 pandemic is in progress," said Chief Executive Joseph Papa. Revenue at the company's core Bausch + Lomb/International segment fell 1% to $1.169 billion, and accounted for about 55% of the overall revenue. Salix sales fell 10% to $496 million, while Ortho Dermatologics sales fell 2% to $144 million. The company is still expecting full-year revenue to range from $7.80 billion to $8.00 billion, compared with a FactSet consensus of $7.9 billion. Shares have fallen 42% in the year to date, while the S&P 500 has gained 2.5%.
2:02 a.m. Nov. 3, 2020 - By Ciara Linnane
Coronavirus update: Trump threatens to fire top infectious-disease expert Fauci as U.S. deaths top 231,000 The U.S. ‘could not be positioned more poorly’ for cold winter months, says Dr. Anthony Fauci, irking Trump and White HouseThe U.S. death toll from the coronavirus illness COVID-19 rose above 231,000 on Monday with cases rising in 42 states, as President Donald Trump continued to criticize a key infectious-disease expert and even hinted he might fire him if he wins Tuesday’s presidential election.
Browse topics:

Filter results by

Location

Us (558)

Canada (160)

Europe (120)

Asia Pacific (112)

Eu (94)

China (74)

Issue

General (214)

Markets/exchanges (152)

Market News (146)

Commodities (141)

Bond Market (90)

Economy (81)

Link to MarketWatch's Slice.